We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
On October 20, West and President & CEO, Eric M. Green, were recognized as a Health Care Innovator by the Philadelphia Business Journal.
This award is especially significant, as it honors West as a life sciences leader among its peers in the Greater Philadelphia Region—one of the country’s top areas for healthcare innovation.
West innovation is rooted in the Company’s 93-year history of providing drug containment and delivery solutions to the world’s top pharmaceutical and biotechnology companies. West partners with these customers to support patients with high-quality products that address current and future healthcare challenges, including at-home administration, patient adherence, dosing accuracy and safety.
One particular area of innovation where West has taken a leading role in the pharmaceutical industry is Connected Health. Through a collaboration with HealthPrize Technologies, West is pioneering novel, electronically connected, wearable drug delivery systems to tackle a massive challenge in healthcare: medication adherence.
Getting patients to adhere to a prescribed medication regimen has always been a challenge. But with the rise of chronic conditions such as diabetes, multiple sclerosis and rheumatoid arthritis – which often require regular self-administration of injectable medication by patients – it’s becoming an even more critical issue. Self-injection devices allow treatments for many conditions to be delivered by the patient themselves at home or another location outside of the doctor’s office. However, if a patient doesn’t use the self-injection device, or uses it improperly, their care may be impacted.
The Health Care Innovator and Doctors of Distinction Awards were presented during a luncheon at the Philadelphia Convention Center where Eric Resnick, VP & Chief Technology Officer, Innovation & Technology, accepted the award on Eric Green’s behalf. Joining Eric Resnick were leaders from the Global Biologics and Innovation & Technology teams. West was among a distinguished group of Innovators from all sectors including: hospitals, pharmaceutical manufacturers, health insurance providers, biotech, medical device manufacturers, and other life science organizations. Honorees included Jefferson Health, Cardiology Consultants of Philadelphia, Inovio Pharmaceuticals, and L.E.A.F. Pharmaceuticals—to name a few.
West is extremely grateful for this honor. To learn more about previous honorees, visit the Philadelphia Business Journal online.
For the tenth consecutive year, teams from West Pharmaceutical Services are raising funds to support research at Fox Chase Cancer Center in Philadelphia. With the support of our families, friends and neighbors, the West team has raised nearly $1 million for Fox Chase since 2004.
In the pharmaceutical industry, safety and quality are paramount. One critical aspect of ensuring the safety of pharmaceutical products is extractables and leachables (E&L) testing. This testing process examines the potential migration of substances from containers, packaging materials, and drug delivery systems into the drug products themselves. By understanding the reasoning behind E&L testing, we can appreciate its role in protecting public health and enhancing customer trust. West Pharmaceutical Services, Inc. is a leader in developing comprehensive studies to evaluate container closure systems in real world simulations, providing customers with a better understanding of their leachable profile and how that could affect drug stability.
<p>We are very pleased to introduce our newly redesigned and enhanced website: <a href="https://www.westpharma.com">www.westpharma.com</a>. </p><p>Our commitment to customers guides everything that we do – and our website is no different. The new and improved site offers a fresh look with easy navigation, mobile optimization and expanded digital capabilities to improve the customer experience.</p>
Understanding the different compendial and standards requirements, and how they influence the final delivery of parenteral drug products, is critical for ensuring patient safety. There are ongoing efforts to harmonize national pharmacopoeia and international standards, driven in large measure by the continuous technological developments in the pharmaceutical industry. Harmonization efforts can be treated differently depending upon the country and working group, and in some cases larger differences result. Staying aware of changes and differences can be a challenge.
In 2011, the US FDA issued an advisory regarding the potential formation of glass lamellae in vials containing injectable drugs. This was in response to several drug recalls in 2010-11. The number of glass-related drug recalls has since declined greatly. This no doubt is due to key actions taken by pharmaceutical manufacturers before the drug goes to market, even during the development phases.
English
Chinese
